Induction chemotherapy in patients with locally-advanced head and neck squamous cell carcinoma: docetaxel and cisplatin.
- Author:
Young Jin CHOI
1
;
Ho Jin SHIN
;
Joo Seop CHUNG
;
Goon Jae CHO
;
Byung Joo LEE
;
Soo Geon WANG
Author Information
1. Department of Internal Medicine, Pusan National University College of Medicine, Busan, Korea. hemon@pusan.ac.kr
- Publication Type:Original Article
- Keywords:
Docetaxel;
Cisplatin;
Head and neck cancer;
Induction chemotherapy
- MeSH:
Carcinoma, Squamous Cell*;
Cisplatin*;
Drug Therapy;
Febrile Neutropenia;
Head and Neck Neoplasms;
Head*;
Humans;
Induction Chemotherapy*;
Neck*;
Neutropenia;
Prospective Studies;
Radiotherapy;
Survival Rate;
Time-to-Treatment
- From:Korean Journal of Medicine
2007;73(4):415-422
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: This prospective study was conducted to assess the efficacy and toxicity of induction chemotherapy with docetaxel and cisplatin for patients with previously untreated, locally advanced squamous cell carcinoma of the head and neck (SCCHN). METHODS: Forty four patients received 120 courses of treatment with docetaxel (70 mg/m2 in a 1-hour infusion) and cisplatin (75 mg/m2 in a 1-hour infusion), repeated every 3 weeks. Responsive patients (complete response: CR, or partial response: PR) received one more course of chemotherapy before undergoing local radiotherapy. RESULTS: All 44 patients were assessable for response and toxicity analysis. The most common grade 3/4 adverse events were neutropenia, which occurred in 23 patients. Four cases of febrile neutropenia were noted. The overall response rate was 90% (CR 45% & PR 45%). The four year probability of time to treatment failure was 56.3+/-10.2%. The four year estimated overall survival rates were 87.4+/-6.9%. CONCLUSIONS: Docetaxel and cisplatin induction chemotherapy shows considerable CR, with an acceptable toxicity profile in patients with locally advanced head and neck squamous cell carcinoma.
